Cargando…

Comparative analysis of safety and efficacy of Alcaftadine 0.25%, Olopatadine hydrochloride 0.2% and Bepotastine besilate 1.5% in allergic conjunctivitis

PURPOSE: To compare the efficacy and safety of Alcaftadine 0.25%, Olopatadine hydrochloride 0.2%, and Bepotastine besilate 1.5% ophthalmic solutions in the treatment of allergic conjunctivitis. METHODS: This is a prospective, observer-masked, comparative study of 180 patients with mild to moderate a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ayyappanavar, Shruti, Sridhar, Sriya, Kumar, Kiran, Jayanthi, C R, Gangasagara, Suresh Babu, Rathod, B L Sujatha, Preethi, B, Mittal, Preeti
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Wolters Kluwer - Medknow 2021
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7933849/ https://www.ncbi.nlm.nih.gov/pubmed/33463568 http://dx.doi.org/10.4103/ijo.IJO_2083_20

Ejemplares similares

Observer-masked trial comparing efficacy of topical olopatadine (0.1%), bepotastine (1.5%), and alcaftadine (0.25%) in mild to moderate allergic conjunctivitis
por: Dudeja, Lakshey, et al.
Publicado: (2019)

Comparative efficacy of bepotastine besilate 1.5% ophthalmic solution versus olopatadine hydrochloride 0.2% ophthalmic solution evaluated by patient preference
por: McCabe, Craig F, et al.
Publicado: (2012)

Efficacy and Toxicity Evaluation of Bepotastine Besilate 1.5% Preservative-Free Eye Drops Vs Olopatadine Hydrochloride 0.2% Bak-Preserved Eye Drops in Patients with Allergic Conjunctivitis
por: Marini, María Cecilia, et al.
Publicado: (2023)

Ocular Itch Relief with Alcaftadine 0.25% Versus Olopatadine 0.2% in Allergic Conjunctivitis: Pooled Analysis of Two Multicenter Randomized Clinical Trials
por: McLaurin, Eugene B., et al.
Publicado: (2014)

Evaluation of alcaftadine 0.25% ophthalmic solution in acute allergic conjunctivitis at 15 minutes and 16 hours after instillation versus placebo and olopatadine 0.1%
por: Greiner, Jack V, et al.
Publicado: (2011)

Treatment of allergic conjunctivitis with bepotastine besilate ophthalmic solution 1.5%
por: Bergmann, Mark T, et al.
Publicado: (2014)

A multicenter evaluation of the efficacy and duration of action of alcaftadine 0.25% and olopatadine 0.2% in the conjunctival allergen challenge model
por: Ackerman, Stacey, et al.
Publicado: (2013)

Update and clinical utility of alcaftadine ophthalmic solution 0.25% in the treatment of allergic conjunctivitis
por: Chigbu, DeGaulle I, et al.
Publicado: (2015)

Bepotastine besilate ophthalmic solution 1.5% for alleviating nasal symptoms in patients with allergic conjunctivitis
por: Cavet, Megan E, et al.
Publicado: (2018)

Comparison of effects of alcaftadine and olopatadine on conjunctival epithelium and eosinophil recruitment in a murine model of allergic conjunctivitis
por: Ono, Santa J, et al.
Publicado: (2011)

Treatment of allergic conjunctivitis with olopatadine hydrochloride eye drops
por: Uchio, Eiichi
Publicado: (2008)

Novel Functional Aspect of Antihistamines: The Impact of Bepotastine Besilate on Substance P-Induced Events
por: Kitaba, Shun, et al.
Publicado: (2009)

Allergic contact dermatitis of both eyes caused by alcaftadine 0.25%: a case report
por: Kim, Jae Hyuk, et al.
Publicado: (2019)

Pooled analysis of two studies evaluating efficacy and safety of olopatadine hydrochloride 0.77% in patients with allergic conjunctivitis
por: McLaurin, Eugene, et al.
Publicado: (2017)

Topical Olopatadine Hydrochloride versus Ketotifen Fumarate for Allergic Conjunctivitis
por: Patel, Dharmistha, et al.
Publicado: (2018)

Effect of alcaftadine 0.25% on ocular itch associated with seasonal or perennial allergic conjunctivitis: a pooled analysis of two multicenter randomized clinical trials
por: Ciolino, Joseph B, et al.
Publicado: (2015)

Efficacy and safety of olopatadine hydrochloride 0.77% in patients with allergic conjunctivitis using a conjunctival allergen-challenge model
por: Torkildsen, Gail, et al.
Publicado: (2015)

Efficacy of 0.05% epinastine and 0.1% olopatadine for allergic conjunctivitis as seasonal and preseasonal treatment
por: Mizoguchi, Takanori, et al.
Publicado: (2017)

Efficacy of olopatadine hydrochloride 0.1%, emedastine difumarate 0.05%, and loteprednol etabonate 0.5% for Chinese children with seasonal allergic conjunctivitis: a randomized vehicle‐controlled study
por: Liu, Rui‐fen, et al.
Publicado: (2016)

The effectiveness of olopatadine hydrochloride eye drops for allergic conjunctivitis: Protocol for a systematic review
por: Zi, Yingxin, et al.
Publicado: (2020)

To evaluate the efficacy and safety of olopatadine 0.1% ophthalmic solution and bepotastine 1.5% ophthalmic solution in patients with vernal keratoconjunctivitis in a tertiary care hospital
por: Sruthi, Vadlakonda, et al.
Publicado: (2020)

Critical appraisal of bepotastine in the treatment of ocular itching associated with allergic conjunctivitis
por: Wingard, Jeremy B, et al.
Publicado: (2011)

Management of allergic conjunctivitis: an evaluation of the perceived comfort and therapeutic efficacy of olopatadine 0.2% and azelastine 0.05% from two prospective studies
por: Epstein, Arthur B, et al.
Publicado: (2009)

Intestinal Anisakiasis Treated Successfully with Prednisolone and Olopatadine Hydrochloride
por: Toyoda, Hideki, et al.
Publicado: (2016)

364 Zero Itch in Eyes Treated With Olopatadine Hydrochloride Ophthalmic Solution, 0.2% in Bilateral Conjunctival Allergen Challenge Studies
por: Blaiss, Michael S., et al.
Publicado: (2012)

Pharmacokinetics and safety of olopatadine hydrochloride 0.77% in healthy subjects with asymptomatic eyes: data from 2 independent clinical studies
por: Meier, Edward, et al.
Publicado: (2017)

Olopatadine ophthalmic solution suppresses substance P release in the conjunctivitis models
por: Tamura, Tadafumi
Publicado: (2012)

Comparison of olopatadine with ketotifen for allergic conjunctivitis: a meta-analysis study
por: Li, Shiyu, et al.
Publicado: (2023)

A Comparative Study of 0.25% Levobupivacaine, 0.25% Ropivacaine, and 0.25% Bupivacaine in Paediatric Single Shot Caudal Block
por: Sharma, Jagdeep, et al.
Publicado: (2018)

Evaluation of Photocatalytic Performance of Nano-Sized Sr(0.9)La(0.1)TiO(3) and Sr(0.25)Ca(0.25)Na(0.25)Pr(0.25)TiO(3) Ceramic Powders for Water Purification
por: Jovanoski Kostić, Aleksandra, et al.
Publicado: (2022)

Maintenance of remission with low-dose olopatadine hydrochloride for itch in well-controlled chronic urticaria
por: Makino, Teruhiko, et al.
Publicado: (2012)

A case report of allergic blepharoconjunctivis to alcaftadine
por: Sandrin, Leda Das Neves Almeida
Publicado: (2015)

Projected 24-hour post-dose ocular itching scores post-treatment with olopatadine 0.7% versus 0.2%
por: Fidler, Matthew L., et al.
Publicado: (2018)

Peculiar Properties of the La(0.25)Ba(0.25)Sr(0.5)Co(0.8)Fe(0.2)O(3−δ) Perovskite as Oxygen Reduction Electrocatalyst
por: Aliotta, Chiara, et al.
Publicado: (2023)

Dynamic Mechanical Properties and Microstructure of an (Al(0.5)CoCrFeNi)(0.95)Mo(0.025)C(0.025) High Entropy Alloy
por: Wang, Bingfeng, et al.
Publicado: (2019)

Olopatadine hydrochloride and rupatadine fumarate in seasonal allergic rhinitis: A comparative study of efficacy and safety
por: Maiti, Rituparna, et al.
Publicado: (2011)

Therapeutic effects of Houttuynia eye drops combined with olopatadine hydrochloride eye drops on vernal keratoconjunctivitis
por: Xu, Xuegu, et al.
Publicado: (2019)

Potential outstanding physical properties of novel black arsenic phosphorus As(0.25)P(0.75)/As(0.75)P(0.25) phases: a first-principles investigation
por: Liu, Fangqi, et al.
Publicado: (2022)

Exchange-bias via nanosegregation in novel Fe(2−x)Mn(1+x)Al (x = −0.25, 0, 0.25) Heusler films
por: Kurdi, S., et al.
Publicado: (2020)

Caudal Epidural Analgesia in Pediatric Patients: Comparison of 0.25% Levobupivacaine and 0.25% Ropivacaine in Terms of Motor Blockade and Postoperative Analgesia
por: Praveen, P., et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_f7vi8hmsti9lfrdo68sjtuj7jg